Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 6,030 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the 4th quarter, HoldingsChannel reports. The firm owned 264,993 shares of the biopharmaceutical company’s stock after selling 6,030 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Gilead Sciences were worth $24,477,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GILD shares. Piper Sandler boosted their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Finally, UBS Group lifted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last 90 days. Insiders own 0.29% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $105.87 on Friday. The business’s fifty day moving average is $103.33 and its 200 day moving average is $93.56. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market cap of $131.84 billion, a price-to-earnings ratio of 286.14, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.